Vowst’s FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection-Reference-Cited by-同舟云学术

Vowst’s FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection

Published:2023-10-17 Issue:12 Volume:85 Page:5852-5854
ISSN:2049-0801
Container-title:Annals of Medicine & Surgery
language:en
Short-container-title:

Author:

Anand Ayush¹²,Parveen Shaikh Nameera³²,Aggarwal Yash⁴²,Fatima Umaima⁵²,Chapagain Sanskriti⁶²,Chidurala Rahul⁷²,Vaghela Jenish⁸,Surana Arihant⁹,Parikh Charmy¹⁰,Patel Raj H.¹¹

Affiliation:

1. B.P. Koirala Institute of Health Sciences, Dharan

2. Global Consortium of Medical Education and Research, Pune, India

3. Batumi Shota Rustaveli State University, Batumi, Georgia

4. Government Institute of Medical Sciences, Greater Noida

5. Shadan Institute of Medical Sciences, Hyderabad, Telangana

6. Devdaha Medical College and Research Institute, Rupandehi, Nepal

7. Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India

8. B.J. Medical College, Ahmedabad, Gujarat

9. Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts

10. Department of Internal Medicine, Carle BroMenn Medical Center, Normal, Illinois

11. Department of Internal Medicine, St. Mary Medical Center, Pennsylvania, USA

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,Surgery

Reference22 articles.

1. Clostridium difficile infection;Leffler;N Engl J Med,2015

2. Clostridium difficile infection;Smits;Nat Rev Dis Primers,2016

3. Global prevalence of Clostridioides difficile in 17,148 food samples from 2009 to 2019: a systematic review and meta-analysis;Borji;J Health Popul Nutr,2023

4. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection;Crobach;Clin Microbiol Infect,2016

5. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI;Finn;BMC Infect Dis,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review;Health Science Reports;2024-09